Subgroup analyses stratified by age groups, intervention durations, BMI categories, and indications for T2DM or obesity treatment more often indicated no association between GLP-1 RAs use and increased risk of esophageal cancer. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.